Evaluation of risk factors in patients with vitamin K-dependent coagulopathy presumed to be caused by exposure to brodifacoum |
Lee, Hee-Jeong
(Division of Hematology and Oncology, Department of Internal Medicine, Chosun University Hospital)
You, Mi-Ra (Division of Hematology and Oncology, Department of Internal Medicine, Chosun University Hospital) Moon, Woo-Ram (Division of Hematology and Oncology, Department of Internal Medicine, Chosun University Hospital) Sul, Hyoung (Division of Hematology and Oncology, Department of Internal Medicine, Chosun University Hospital) Chung, Choon-Hae (Division of Hematology and Oncology, Department of Internal Medicine, Chosun University Hospital) Park, Chi-Young (Division of Hematology and Oncology, Department of Internal Medicine, Chosun University Hospital) Park, Sang-Gon (Division of Hematology and Oncology, Department of Internal Medicine, Chosun University Hospital) |
1 | Hadler MR, Shadbolt RS. Novel 4-hydroxycoumarin anticoagulants active against resistant rats. Nature 1975;253:275-277. DOI ScienceOn |
2 | Rauch AE, Weininger R, Pasquale D, et al. Superwarfarin poisoning: a significant public health problem. J Community Health 1994;19:55-65. DOI ScienceOn |
3 | Abell TL, Merigian KS, Lee JM, Holbert JM, McCall JW 3rd. Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report. J Toxicol Clin Toxicol 1994;32:69-73. DOI ScienceOn |
4 | Kim HY, Jeon HJ, Ko BS, Lee KH, Kim ST. Two cases of brodifacoum poisoning from inhalation route. Korean J Hematol 1996;31:473-479. |
5 | Chua JD, Friedenberg WR. Superwarfarin poisoning. Arch Intern Med 1998;158:1929-1932. DOI ScienceOn |
6 | Pavlu J, Harrington DJ, Voong K, Savidge GF, Jan-Mohamed R, Kaczmarski R. Superwarfarin poisoning. Lancet 2005;365:628. DOI ScienceOn |
7 | Lipton RA, Klass EM. Human ingestion of a 'superwarfarin' rodenticide resulting in a prolonged anticoagulant effect. JAMA 1984;252:3004-3005. DOI ScienceOn |
8 | Bruno GR, Howland MA, McMeeking A, Hoffman RS. Long-acting anticoagulant overdose: brodifacoum kinetics and optimal vitamin K dosing. Ann Emerg Med 2000;36:262-267. DOI ScienceOn |
9 | Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giff in SL. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila) 2010;48:979-1178. DOI ScienceOn |
10 | Park BK, Leck JB. A comparison of vitamin K antagonism by warfarin, difenacoum and brodifacoum in the rabbit. Biochem Pharmacol 1982;31:3635-3639. DOI ScienceOn |
11 | Bachmann KA, Sullivan TJ. Dispositional and pharmacodynamic characteristics of brodifacoum in warfarin- sensitive rats. Pharmacology 1983;27:281-288. DOI |
12 | Hui CH, Lie A, Lam CK, Bourke C. 'Superwarfarin' poi-soning leading to prolonged coagulopathy. Forensic Sci Int 1996;78:13-18. DOI ScienceOn |
13 | Wu YF, Chang CS, Chung CY, Lin HY, Wang CC, Shen MC. Superwarfarin intoxication: hematuria is a major clinical manifestation. Int J Hematol 2009;90:170-173. DOI ScienceOn |
14 | Jin MC, OuYang XK, Chen XH. High-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry for the determination of flocoumafen and brodifacoum in whole blood. J Appl Toxicol 2007;27:18-24. DOI ScienceOn |
15 | Olmos V, Lenzken SC, del Carmen Paz M, et al. Quantification of brodifacoum, bromadiolone and difenacoum in human serum by HPLC with ultraviolet and fluorometric detection. Acta Toxicol Argent 2004;12:9-14. |
16 | Watt BE, Proudfoot AT, Bradberry SM, Vale JA. Anticoagulant rodenticides. Toxicol Rev 2005;24:259-269. DOI ScienceOn |
17 | Eason CT, Murphy EC, Wright GR, Spurr EB. Assessment of risks of brodifacoum to non-target birds and mammals in New Zealand. Ecotoxicology 2002;11:35-48. DOI ScienceOn |
18 | Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74. DOI ScienceOn |
19 | Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007;7:99-111. DOI ScienceOn |
20 | Makris M, Watson HG. The management of coumarin- induced over-anticoagulation Annotation. Br J Haematol 2001;114:271-280. DOI ScienceOn |
21 | O'Bryan SM, Constable DJ. Quantif ication of brodifacoum in plasma and liver tissue by HPLC. J Anal Toxicol 1991;15:144-147. DOI |
22 | Lieber CS. Alcohol and the liver: 1994 update. Gastroenterology 1994;106:1085-1105. DOI |
23 | Weathermon R, Crabb DW. Alcohol and medication interactions. Alcohol Res Health 1999;23:40-54. |
24 | Schalekamp T, Klungel OH, Souverein PC, de Boer A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008;168:180-185. DOI ScienceOn |
25 | Dalton SO, Sorensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it inf luence prescribing? CNS Drugs 2006;20:143-151. DOI ScienceOn |
26 | Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry 1998;59 Suppl 15:19-27. |
27 | Hong J, Yhim HY, Bang SM, et al. Korean patients with superwarfarin intoxication and their outcome. J Korean Med Sci 2010;25:1754-1758. DOI ScienceOn |
28 | Choi KH, Kim AJ, Son IJ, et al. Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting. J Korean Med Sci 2010;25:337-341. |
29 | O'Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med 1984;144:989-991. DOI |
30 | Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin- drug interactions. Chem Res Toxicol 1992;5:54-59. DOI ScienceOn |
31 | Hungin AP, Rubin GP, O'Flanagan H. Co-prescription of H2 receptor blockers and proton pump inhibitors with warfarin in general practice. Postgrad Med J 1999;75:721-722. DOI |
32 | Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004;427:541-544. DOI ScienceOn |
33 | Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;427:537-541. DOI ScienceOn |
34 | D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-649. DOI ScienceOn |
35 | Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation- related outcomes during warfarin therapy. JAMA 2002;287:1690-1698. DOI ScienceOn |
36 | Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008;84:326-331. DOI ScienceOn |
37 | Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008;25:45-51. DOI |
38 | Visser LE, van Vliet M, van Schaik RH, et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004;14:27-33. DOI |
39 | Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997;7:361-367. DOI |
40 | Zupancic-Salek S, Kovacevic-Metelko J, Radman I. Successful reversal of anticoagulant effect of superwarfarin poisoning with recombinant activated factor VII. Blood Coagul Fibrinolysis 2005;16:239-244. DOI ScienceOn |
41 | Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-719. DOI ScienceOn |
42 | Spahr JE, Maul JS, Rodgers GM. Superwarfarin poisoning: a report of two cases and review of the literature. Am J Hematol 2007;82:656-660. DOI ScienceOn |
43 | Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 2007;81:185-193. DOI ScienceOn |
![]() |